Skip to main navigation
Skip to search
Skip to main content
Penn State Home
Help & FAQ
Home
Researchers
Research output
Research units
Equipment
Grants & Projects
Prizes
Activities
Search by expertise, name or affiliation
Amiodarone: What have we learned from clinical trials?
Gerald V. Naccarelli
,
Deborah L. Wolbrette
, Joseph T. Dell'Orfano
, Hemantkumar M. Patel
, Jerry C. Luck
Department of Medicine
Division of Cardiology
Penn State Heart and Vascular Institute
Research output
:
Contribution to journal
›
Review article
›
peer-review
31
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Amiodarone: What have we learned from clinical trials?'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Amiodarone
100%
Antiarrhythmic Agents
12%
Antiarrhythmic Drugs
12%
Clinical Trials
100%
Congestive Heart Failure
25%
Electrophysiological Study
12%
Holter
12%
Implantable Cardioverter-defibrillator Therapy
12%
Implantable Defibrillator
12%
Improved Survival
12%
Nonsustained Ventricular Tachycardia
12%
Overall Mortality
12%
Overall Survival
12%
Post-myocardial Infarction
12%
Recurrence Rate
12%
Supraventricular Arrhythmia
12%
Ventricular Arrhythmia
12%
Pharmacology, Toxicology and Pharmaceutical Science
Amiodarone
100%
Antiarrhythmic Agent
25%
Clinical Trial
100%
Congestive Heart Failure
25%
Heart Ventricle Tachycardia
25%
Infarction
12%
Overall Survival
12%
Recurrence Risk
12%
Supraventricular Tachycardia
12%
Nursing and Health Professions
Amiodarone
100%
Antiarrhythmic Agent
25%
Congestive Heart Failure
12%
Heart Ventricle Tachycardia
25%
Implantable Cardioverter Defibrillator
25%
Infarction
12%
Overall Survival
12%
Patient with Congestive Heart Failure
12%
Recurrence Risk
12%
Supraventricular Tachycardia
12%